Fig 3. Effectiveness of lusutrombopag therapy to raise platelet counts and to avoid transfusion stratified by baseline platelet counts and spleen index.

(A) The maximum platelet value after lusutrombopag treatment and prior to the invasive procedures stratified by baseline platelet counts. There was a significant difference between patients with baseline platelet count ≤30,000/μL (n = 8) and >30,000/μL (n = 17) (p<0.01). (B) The proportion of patients who needed platelet transfusion stratified by baseline platelet counts and spleen index. There was a significant difference between patients with spleen index ≥41 and <41 among patients with baseline platelet count ≤30,000/μL (p = 0.02) but not in >30,000/μL (p<0.01).